Mon, Feb 16, 2026
Volume 12, Issue 1 (Winter 2026 2026)
Caspian J Neurol Sci 2026, 12(1): 1-16 |
Back to browse issues page
Ethics code: NA
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Narayanan M, Rajinikanth V. Proteomic Biomarkers for Sustainable Diagnosis of Major Neurodegenerative Disorders: A Review. Caspian J Neurol Sci 2026; 12 (1) :1-16
URL: http://cjns.gums.ac.ir/article-1-793-en.html
URL: http://cjns.gums.ac.ir/article-1-793-en.html
1- Department of Biotechnology, Research and Innovation, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India , mathimicro@gmail.com
2- Department of Biotechnology, Research and Innovation, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
2- Department of Biotechnology, Research and Innovation, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
Abstract: (31 Views)
Background: Neurodegenerative illnesses, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), are marked by progressive neuronal degeneration and presently lack adequate diagnostic and prognostic instruments.
Objectives: This review analyzed recent developments in proteomic methodologies and their uses in the identification and validation of biomarkers for AD, PD, and ALS. It offers a comparative proteome analysis of several significant neurodegenerative illnesses, highlighting both common and unique molecular markers. The review identified translational obstacles from biomarker discovery to clinical use, providing information that can improve comprehension of disease mechanisms and inform the creation of viable therapeutic options.
Materials & Methods: A thorough literature analysis was performed on proteomic studies concerning cerebrospinal fluid (CSF), blood, urine, and brain tissue in patients with AD, PD, and ALS. The review examined papers from January 2020 to June 2025 across prominent databases utilizing specified proteomic terminology. The inclusion criteria mandated that studies concentrate on human or validated animal proteomic analysis of disease-specific biomarkers. The literature underwent qualitative analysis to discern prevalent biomarkers, developing molecular networks, and trends among the three disorders, highlighting translational significance and methodological advancements.
Results: Comparative proteomic investigations demonstrated both shared and unique molecular pathways across AD, PD, and ALS, including synaptic degradation, mitochondrial dysfunction, and neuroinflammation. The amalgamation of proteomic data with genomic, systems biology, and transcriptomic, methodologies is expediting the identification of therapeutically pertinent biomarker panels. Innovative methods, like single-cell proteomics and artificial intelligence-based analysis are improving sensitivity and specificity in biomarker detection.
Conclusion: The proteomic biomarkers offer considerable potential for early diagnosis, disease classification, and tailored therapy approaches in neurodegenerative disorders. Addressing existing translational obstacles will be essential for the effective application of precision medicine in neurodegeneration.
Objectives: This review analyzed recent developments in proteomic methodologies and their uses in the identification and validation of biomarkers for AD, PD, and ALS. It offers a comparative proteome analysis of several significant neurodegenerative illnesses, highlighting both common and unique molecular markers. The review identified translational obstacles from biomarker discovery to clinical use, providing information that can improve comprehension of disease mechanisms and inform the creation of viable therapeutic options.
Materials & Methods: A thorough literature analysis was performed on proteomic studies concerning cerebrospinal fluid (CSF), blood, urine, and brain tissue in patients with AD, PD, and ALS. The review examined papers from January 2020 to June 2025 across prominent databases utilizing specified proteomic terminology. The inclusion criteria mandated that studies concentrate on human or validated animal proteomic analysis of disease-specific biomarkers. The literature underwent qualitative analysis to discern prevalent biomarkers, developing molecular networks, and trends among the three disorders, highlighting translational significance and methodological advancements.
Results: Comparative proteomic investigations demonstrated both shared and unique molecular pathways across AD, PD, and ALS, including synaptic degradation, mitochondrial dysfunction, and neuroinflammation. The amalgamation of proteomic data with genomic, systems biology, and transcriptomic, methodologies is expediting the identification of therapeutically pertinent biomarker panels. Innovative methods, like single-cell proteomics and artificial intelligence-based analysis are improving sensitivity and specificity in biomarker detection.
Conclusion: The proteomic biomarkers offer considerable potential for early diagnosis, disease classification, and tailored therapy approaches in neurodegenerative disorders. Addressing existing translational obstacles will be essential for the effective application of precision medicine in neurodegeneration.
Type of Study: Review |
Subject:
Special
Received: 2025/06/30 | Accepted: 2025/11/23 | Published: 2026/01/11
Received: 2025/06/30 | Accepted: 2025/11/23 | Published: 2026/01/11
Send email to the article author
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
